Da Zen Theranostics Inc
We have developed a highly effective anti-cancer drug that we believe will treat many forms of cancer and cancer metastasis more effectively than currently therapy. (See Section 3 for the details of our patented technology.) Our approach to the development and testing of anti-cancer drugs in a clinical trial setting is unique. Our proprietary products and processes enable more effective identification, targeting, and treatment of cancer, regardless of tumor location and type. Our advanced technology allows us to cost-effectively develop new, specific cancer therapies – essentially a platform giving us competitive and sustainable advantage to develop better anti-cancer drugs more quickly and safely
The DaZen technology is the collaborative result of three Institutions that have spent years in cancer research: Georgia State University, Emory University, and Cedars Sinai Medical Center. Together there are one granted patent and six patent applications that have been licensed exclusively the DaZen Company. Dr. Leland W.K. Chung, the inventors of all seven patents and a worldwide renowned prostate cancer researcher, wanted to bring the cumulative lifetime of research work and the six applications to the world. The results of his research and patents have been confirmed in animals at other independent laboratories. The technology of this successful research and its associated patents are now available for commercial release, after being created using grant-funded R&D by our scientific team at the aforementioned Institutions. All of our company's research up to now, amounting to over 10 years of work, has been funded by Institutions with non-dilutive equity. After establishing DaZen Dr. Chung and his associates filed three more patent applications of the proprietary platform technology. All together, the DaZen Company owns a total of ten patents of which eight patent applications and two granted patents. Of the ten patents seven exclusively licensed and three proprietary to the company. Dr. Chung is currently the Chairman of Board of DaZen.
Since we have already completed many years of research, we are now poised to conduct pre-clinical studies of investigational new drug (IND) in a GLP facility with the intent to file IND applications in late 2020, and to work with clinics and hospitals to begin human clinical trials of our targeted therapies in 2021, aided by new companion diagnostic biomarkers for patient selection and monitoring therapeutic response. We will proceed to treat consenting patients with our targeted agents as soon as we successfully complete our IND application.
As a brief illustration of our unique approach of developing new anti-cancer drug for cancer patients, our targeted drug has unique properties that precisely deliver the chosen drug to localized and distantly disseminated cancer cells without damaging normal tissues and organs, to overcome therapeutic resistance by cancer cells to therapy, and to confirm the response to therapy by monitoring a serum companion diagnostic biomarker. If the response is positive, we will look at the patient’s genetic profiling and select the next patients based on their responsiveness and the molecular signatures being gathered in the database for future patient selection. This method would progressively increase the response rate of our patients and greatly improve patient survival rates in our forthcoming clinical trials, scheduled in 2021, leading to more rapid FDA approval.
We are confident that our strategy will work in cancer patients because the therapeutic drugs such as Simvastatin and Cisplatin conjugated to our cancer targeting dye-carrier are already FDA approved. Hitherto, some patients have experienced drug toxicity and others have developed drug resistance. We have overcome both of these limitations by improving the delivery of targeted drugs exclusively to cancer cells, with the drugs confined to the cancer cells for much longer periods than current therapies (up to 3 weeks or one month), with no evidence of toxicity to normal organs and tissues. We have also demonstrated that our targeted drugs can overcome therapeutic resistance by cancer cells to a broad spectrum of therapies, such as chemotherapy, hormonal therapy and targeted therapies with tyrosine kinase inhibitors, Gefitnib, Icotinib and Everolimus. This successful broad-spectrum re-sensitization to therapeutic agents has prompted us to search for the molecular mechanisms of re-sensitization. Presently it appears our targeted drugs promote programmed cell death by altering mitochondrial and lysosomal functions, as shown by our previous research on drug targeting. While our laboratories continue to search for further mechanisms of re-sensitization for various classes of therapeutic agents used to treat cancer patients, we would like to stress that our new drug targeting technology can improve cancer patient responses and survival now. There is an urgent need to test and develop our targeted drug system in rigorous clinical trials, moving our discoveries from the laboratory to the clinic to save the lives of millions who suffer from mortality and morbidity of cancer.